References
  1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians.2018; 68(6):394–424.
  2. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology (NCCN guidelines): Non-small cell lung cancer. Version 6. 8 17. https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed 5 July 2020.
  3. Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non- small-cell lung cancer. J Clin Oncol 2010;28:3138-45.
  4. Berry MF, Coleman BK, Curtis LH, Worni M, D’Amico TA, Akushevich I. Berry MF, Coleman BK, Curtis LH, Worni M, D’Amico TA, Akushevich I. Benefit of adjuvant chemotherapy after resection of stage II (T1-2N1M0) non-small cell lung cancer in elderly patients. Ann Surg Oncol. 2015;22(2):642-648.
  5. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552-3559.
  6. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351-360.
  7. Pu, C. Y., & Yendamuri, S. Neoadjuvant versus adjuvant chemotherapy for resectable non-small cell lung cancer debate revisited. Journal of Thoracic Disease. 2019;11(12):5646–5648.
  8. Subramanian, M. P., & Puri, V. Neoadjuvant vs. adjuvant chemotherapy in locally advanced non-small cell lung cancer-is timing everything? Journal of Thoracic Disease. 2019;11(12): 5674–5676.
  9. NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet, 2014;383:1561-71.
  10. Brandt, W. S., Yan, W., Zhou, J., Tan, K. S., Montecalvo, J., Park, B. J., … Jones, D. R. Outcomes Following Neoadjuvant or Adjuvant Chemotherapy for cT2-4N0-1 Non-Small Cell Lung Cancer: A Propensity-Matched Analysis. J Thorac Cardiovasc Surg. 2020;157(2):743–753.
  11. Westeel, V., Quoix, E., Puyraveau, M., Lavolé, A., Braun, D., Laporte, S., Milleron, B. A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial). European Journal of Cancer. 2013;49(12):2654–2664.
  12. Lim E, Harris G, Patel A, Adachi I, Edmonds L, Song F. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol. 2009;4(11):1380-1388.
  13. Zhang XN, Huang L. Neoadjuvant chemotherapy followed by surgery versus upfront surgery in non-metastatic non-small cell lung cancer: systematic review and meta-analysis of randomized controlled trials. Oncotarget. 2017;8(52):90327-90337.
  14. Tran AQ, Erim DO, Sullivan SA, et al. Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase. Gynecol Oncol. 2018;148(2):329-335.
  15. Cole, A. L., Barber, E. L., Gogate, A., Tran, A. Q., & Wheeler, S. B. Economic Analysis of Neoadjuvant Chemotherapy Versus Primary Debulking Surgery for Advanced Epithelial Ovarian Cancer Using an Aggressive Surgical Paradigm. International Journal of Gynecological Cancer. 2018; 28(6): 1077–1084.
  16. Rowland, M. R., Lesnock, J. L., Farris, C., Kelley, J. L., & Krivak, T. C. Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older. American Journal of Obstetrics and Gynecology. 2015; 212(6):763.e1-763.e8.
  17. Poonawalla, I. B., Lairson, D. R., Chan, W., Piller, L. B., & Du, X. L. Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer. Value in Health. 2015; 18(4):387–395.
  18. Onisim, A., Achimas-Cadariu, P., Iancu, M., Puscas, E., Bodog, A., & Vlad, C. Clinical outcomes and cost-effectiveness of primary treatment of ovarian cancer in North-Western Romania. Journal of BUON. 2019; 24(3):982–990.
  19. Forde GK, Chang J, Ziogas A. Cost-effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage IIIC and IV epithelial ovarian cancer. Clinicoecon Outcomes Res. 2016;8:397-406.
  20. Himmel, M., Hartmann, M., & Guntinas-Lichius, O. Cost effectiveness of neoadjuvant chemotherapy in locally advanced operable head and neck cancer followed by surgery and postoperative radiotherapy: A Markov model-based decision analysis. Oncology (Switzerland). 2013;84(6):336–341.
  21. Denduluri, N., Patt, D. A., Wang, Y., Bhor, M., Li, X., Favret, A. M., Lyman, G. H. (2015). Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices. JNCCN Journal of the National Comprehensive Cancer Network. 2015; 13(11):1383–1393.
  22. Grutters, J. P. C., Joore, M. A., Wiegman, E. M., Langendijk, J. A., De Ruysscher, D., Hochstenbag, M., Pijls-Johannesma M. (2010). Health-related quality of life in patients surviving non-small cell lung cancer. Thorax. 2010;65(10):903–907.
  23. Paracha N, Abdulla A, MacGilchrist KS. Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients. Health Qual Life Outcomes. 2018;16(1):179.
  24. Handorf, E. A., McElligott, S., Vachani, A., Langer, C. J., Bristol Demeter, M., Armstrong, K., & Asch, D. A. Cost Effectiveness of Personalized Therapy for First-Line Treatment of Stage IV and Recurrent Incurable Adenocarcinoma of the Lung. Journal of Oncology Practice. 2012;8(5):267–274.
  25. Lugg, S. T., Agostini, P. J., Tikka, T., Kerr, A., Adams, K., Bishay, E., Naidu, B. Long-term impact of developing a postoperative pulmonary complication after lung surgery. Thorax. 2016;71(2):171–176.
  26. Xin, L., Jufang, S., Jian, Y., & Wanqing, C. Influencing Factors of Hospitalization Expenses of Surgical Lung Cancer Patients:An Analysis of 5222 Cases. China Cancer. 2019:28(12):922–926.
  27. National Institutes of Health, National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE). https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50. Accessed 5 July 2020.
  28. Chinese Society Oncology Cancer (CSCO). Guideline of Chinese Society Oncology Cancer (CSCO) Primary Lung Cancer. People’s Medical Publishing House; 2019.
  29. Shanghai municipal health commission. Medical programs fee schedule (MPFS). http://wsjkw.sh.gov.cn/ylsfbz/index.html. 2017. Accessed 5 July 2020.
  30. Briggs, AH., Claxton, K., Sculpher, MJ. Decision modelling for health economic evaluation. Oxford University Press; 2006.
  31. Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumor load (SCORPION trial): Final analysis of peri-operative outcome. Eur J Cancer. 2016; 59:22–33.